Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
Condition: Non-small Cell Lung Cancer (NSCLC) Intervention: Drug: 80mg Osimertinib Sponsors: Samsung Medical Center; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Research